NSE
BSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
IOL Chemicals & Pharmaceuticals delivers strong top-line and profit growth in Q1 FY27, driven by pharma demand and restored pricing power, despite rising input costs.
Consolidated revenue grew from ₹551.7 Cr in Q1 FY26 to ₹756.3 Cr in Q1 FY27, driving strong top-line expansion.
Consolidated cost of materials consumed surged from ₹356.7 Cr in Q3 FY26 to ₹506.8 Cr in Q1 FY27, signaling sharp input cost inflation.
Pharmaceuticals EBIT climbed from ₹34.5 Cr in Q3 FY26 to ₹68.8 Cr in Q1 FY27, signaling a strong segment turnaround.
Consolidated other expenses jumped from ₹83.7 Cr in Q3 FY26 to ₹103.5 Cr in Q1 FY27, signaling rising operational overheads.
Consolidated EBITDA margin expanded from 10.7% in Q3 FY26 to 14.6% in Q1 FY27, reflecting restored pricing power.
Consolidated inventory changes swung from 25.6 Cr in Q3 FY26 to -29.5 Cr in Q1 FY27, signaling active stock drawdown.
Consolidated EPS rebounded from ₹0.70 in Q3 FY26 to ₹2.20 in Q1 FY27, driving shareholder value.
Consolidated employee benefits expense rose from ₹56.9 Cr in Q3 FY26 to ₹71.2 Cr in Q1 FY27, indicating ongoing workforce expansion.